Hosted on MSN
Aflac signals sustained Japan sales momentum with Miraito cancer product and targets recovery to pre-pandemic levels
Daniel Paul Amos, Chairman and CEO, reported net earnings per diluted share of $1.11 and adjusted earnings per diluted share of $1.78 for Q2 2025, describing these as “solid results for the quarter, ...
Aflac Incorporated AFL reported second-quarter 2025 adjusted earnings per share (EPS) of $1.78, which surpassed the Zacks Consensus Estimate by 4.1%. However, the bottom line decreased 2.7% year over ...
CEO Dan Amos highlighted strong performance for the year, with net earnings per diluted share rising 23.8% and adjusted earnings per diluted share increasing 15.7%. Aflac Japan accounted for over 70% ...
Insurers often require cancer patients to “fail” on a less expensive treatment before gaining approval for the medicine their doctor originally prescribed. The result is delayed care. Cancer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback